Pay in 4 interest-free payments of $6.01 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
Korean Firms Diversify with Patches and Oral Drugs, While Global Players Focus on Oral and Combination Therapies South Korean pharmaceutical companies are also accelerating the race to diversify the formulations of GLP-1 agonist treatments for obesity and diabetes
Chapters 5 & 6: Break down revenue analysis at both regional and country levels, offering precise data on market size, growth drivers, and expansion opportunities across global markets
Are there optimal probiotic strains for GLP-1 support
After adjustment for age, sex, baseline BMI, baseline HbA1c, and hepatosteatosis grade, semaglutide remained independently associated with greater percentage weight loss at 6 months (adjusted = 6.16% points
In recent years, the pursuit of health and well-being has taken an innovative turn, especially in the area of weight management
